1	Title: Development of a Core Outcome Measure Instrument; "LeishCOM_LCL", for
2	Localised Cutaneous Leishmaniasis
3	
4	Short Title: Core Outcome Measure Instrument for Localised Cutaneous Leishmaniasis
5	Shalindra Ranasinghe ^{1#Φ} , Sujai Senarathne ^{1Φ} , Vijani Somaratne ² , Charles JN Lacey ³ Surangi
6	Jayakody ⁴ , Amila Wickramasinghe ⁵ , Indira Kahawita ⁶ , Hiro Goto ⁷ , Mitali Chatterjee ⁸ , José AL
7	Lindoso ⁹ , Vivak Parkash ³ , Surya J Chaudhuri ¹⁰ , Renu Wickremasinghe ¹ , Nilay K. Das ¹¹ , Paul M.
8	Kaye ^{3,12} *, Alison M Layton ^{3,5,12} *#
9	1. Department of Parasitology, University of Sri Jayewardenepura, Gangodawila, Nugegoda,
10	10250, Sri Lanka
11	2. Dermatology Unit, District General Hospital, Embilipitiya, 70200, Sri Lanka
12	3. York Biomedical Research Institute, Hull York Medical School, University of York,
13	Heslington, York, YO10 5DD, United Kingdom
14	4. Division of Health Sciences, Warwick Medical School, University of Warwick, Coventry
15	CV4 7AL, United Kingdom
16	5. Harrogate and NHS District Foundation Trust, Harrogate, United Kingdom
17	6. Leprosy clinic, National Hospital, 01000, Sri Lanka
18	7. Department of Preventive Medicine, Faculdade de Medicina, Universidade de São Paulo,
19	Sao Paulo, Brazil
20	8. Department of Pharmacology, Instt of PG Med Education & Research 244B, AJC Bose
21	Road, Kolkata - 700 020, India

22	9. Institute of Infectology Emilio Ribas and Laboratory of Protozoology, Institute of Tropical
23	Medicine (LIM 49 HC-FMUSP), Faculdade de Madicina, Universidade de São Paulo, Sao
24	Paulo, Brazil
25	10. Dept. of Microbiology, Sarat Chandra Chattopadhyay Govt. Medical College & Hospital
26	Uluberia, Howrah, West Bengal 711316 India
27	11. Department of Dermatology, College of Medicine and Sagore Dutta Hospital, Kamarhati,
28	Kolkata 700058, India
29	12. Skin Research Centre, Hull York Medical School, University of York, Heslington, York,
30	YO10 5DD, United Kingdom
31	^Φ First co-authors
32	# Corresponding authors
33	* Senior co-authors
34	Abstract
35	Background: Localized cutaneous leishmaniasis (LCL) is a chronic ulcerating disease. A
36	literature review identified inconsistencies in clinical trials. The aims of this study were to reach a
37	consensus on the most important domains to measure when assessing LCL, agree on parameters
38	to measure the domains, and develop a tool representing a Core Outcome Set (COS), for use in
39	clinical assessment of LCL.
40	Methodology & Principal findings: A literature review was conducted to identify any existing
41	COS for LCL embracing agreed Outcome Domains, i.e. what to measure and any Outcome

43 assessment of LCL were identified through an international collaborative approach using e-

42

44

Measurement Instruments (OMIs). As no COS was available, potential outcome domains for

consultations and virtual discussions with expert stakeholders (n=20) from geographically

different LCL endemic countries. Subsequent judgmental validation process included a face-to-45 face multidisciplinary stakeholders' meeting adopting the Nominal Group Technique. A final 46 47 consensual agreement on outcome domains and items required to measure these domains was established. "Clinical Cure" was defined as the ideal overall "General Concept". The five Core 48 Outcome Domains included Signs capturing clinical morphology, diameter, and induration of an 49 index lesion with the aid of a palpability score, **Treatment Efficacy** assessing percentage change 50 in size of the lesion and re-epithelialization compared to baseline, Treatment Impact which 51 included an investigator and patient visual analogue score, and Clinical Sequelae rating pigment 52 change, atrophic and hypertrophic/keloid scars. It was agreed that two open-ended questions 53 should be included to capture some aspects of Health-Related Quality of Life as a means of 54 55 capturing a patient-focused approach.

56 **Conclusion:** LeishCOM_LCL was generated to reflect a COS for LCL. This captured 57 demographic details, agreed outcome domains and measures to assess these domains. Validation 58 of LeishCOM_LCL will be reported in a separate paper. Development of a Patient Reported 59 Outcome Measure will be considered in the future.

Keywords: Localized Cutaneous Leishmaniasis, Core Outcome Measure Instrument, Core Outcome Domain, Core Outcome Set

62 Author Summary

Localized cutaneous leishmaniasis (LCL) is a chronic ulcerating disease caused by the parasite *Leishmania* spp. Literature review identified inconsistencies in methods and parameters used to evaluate treatment/alternative-interventions resulting in difficulties in comparing new treatment/interventions in clinical trials. In our international consensual study, we adopted the

face-to-face nominal group technique and a judgment process to identify domains key to 67 assessment of LCL. Subsequent measures for each domain were used to form a Core Outcome Set 68 (COS). LeishCOM LCL was developed as an outcome measure instrument (OMI) to capture the 69 COS incorporating existing and newly developed tools. "Clinical Cure" was agreed as the 70 "General Concept" to be captured through five domains. It was agreed that "Signs" domain should 71 capture clinical morphology, diameter, and induration of an index lesion with the aid of a 72 palpability score. "Treatment Efficacy" was assessed by recording percentage change in size of 73 the lesion and re-epithelialization compared to baseline. "Treatment Impact" was reflected through 74 an investigator and the patient visual analogue score and "Clinical Sequelae" rated pigment 75 change, atrophic/hypertrophic scars. Two open-ended questions were included to capture some 76 77 aspects of "Health-Related Quality of Life". CutLeishCOM also records patient demographic details and was validated in a small cohort of patients. 78

79 Introduction

Localized cutaneous leishmaniasis (LCL) is a skin disease caused by an intra-cellular protozoan 80 parasite belonging to the genus *Leishmania* that is transmitted through a bite of an infected female 81 82 phlebotomine sand fly. It is considered a neglected tropical disease and is endemic in 90 countries with an estimated 1 million new cases reported annually [1]. LCL is usually characterized by the 83 presence of amastigotes localized in skin tissue. It appears in exposed areas of the body and 84 85 frequently heals with lifelong scars [1]. This form of presentation does not include mucosal lesions 86 and associated disseminated / diffuse CL or Post Kala-azar Dermal Leishmaniasis [1, 2]. The skin lesions are typically chronic in nature and the disease shows a wide range of clinical features 87 88 ranging from a small papule to extensive ulceration and can often result in permanent physical and 89 psychological sequelae with a potentially life-long impact. Clinicians frequently treat LCL with

the aim of minimizing sequelae such as scarring that may result in disfigurement and social stigma
[3]. Treatment modalities available for LCL include intra-lesional or parenteral pentavalent
antimonial compounds and liposomal amphotericin B as the mainstay of treatment in Old World
LCL while miltefosine and pentamidine are also used in the treatment of New World LCL [4-7].
Cryotherapy and thermotherapy are some of the commonly used non- pharmacological treatment
measures [7].

A review of the clinical trials examining different treatment modalities for LCL found studies to 96 be deficient in design, execution, analysis, and reporting [8]. Furthermore, systematic literature 97 reviews demonstrate that most clinical trials on LCL fail to clearly identify consistent and 98 standardized primary and secondary clinical outcome measures [9-12]. There are a few new 99 treatment/alternative-interventions described for LCL [7,13-15]. However, the results of those 100 101 studies are difficult to compare due to inconsistencies in the methods and the parameters used for the evaluation. Furthermore, most studies have not considered the patients' perspective. 102 103 Recommendations to assess initial response and define timelines to initial clearance and subsequent cure have been suggested as potential important outcomes [16, 17]. The development 104 of a validated scoring system for LCL based on harmonized methodologies would allow 105 assessment of treatment response in routine clinical settings and enable comparison of the efficacy 106 of existing or new drugs as well as novel alternative interventions and would subsequently support 107 108 meta-analysis.

109 Core Outcome Sets (COS) represent agreed standardized outcomes that should be reported for all 110 trials conducted in a specific research area, with the intention of reducing bias and ensuring that 111 data from different trials are suitable for meta-analysis [18]. Various COS which embrace agreed 112 Core Outcome Domains and Core Outcome Measures to assess the domains have been developed

for several dermatological disorders as a means of evaluating the severity and impact of the condition as well as therapeutic response to treatment in a standardized manner. The development of clinical scores through measurable outcomes using clinimetrics and inclusion and scoping out of clinicians' and patients' perspectives results in improved outcome measures [19, 20].

Many measures have been developed based on the cardinal clinical features of each disorder, e.g. 117 the Psoriasis Area and Severity Index (PASI) [21], the Eczema Area and Severity Index (EASI) 118 [22] and the Vitiligo Area Scoring Index (VASI) [23] etc. These instruments only account for the 119 clinical severity of the disease and treatment response but fail to capture the clinical sequelae and 120 the impact of the disease on the quality of life. The Harmonizing Outcome Measures for Eczema 121 (HOME) roadmap was developed and implemented in cooperation with the COMET (Core 122 123 Outcome Measures in Effectiveness Trials) and COSMIN (COnsensus-based Standards for the selection of health Measurement INstruments) research groups, with the aim of developing a 124 standardized, validated and consensus-based roadmap for developing COS for atopic eczema [24]. 125 126 The process developed for the HOME roadmap has been recommended and adopted for other dermatological conditions [19, 24]. However, this approach has rarely been adopted for neglected 127 diseases of the skin. 128

There are currently only two studies that report a harmonized approach to assess LCL, one describing harmonized measurable clinical methodologies to assess the response to interventions in clinical trials [16] and a second follow-up study [25] assessing the capacity of implementation of the harmonized methodologies across several geographic regions. However, the proposed measurable outcomes in these studies have not been validated. In addition, Patient Reported Outcome Measures (PROMs) that qualitatively assess the impact of the disease and / or the response to treatment or adverse effects from therapy were not considered. The absence of sequelae

resulting from LCL is a further gap in current assessments [16, 25]. Therefore, the aim of our study was to reach a consensus on the most important Core Outcome Domains that need to be considered and measured when assessing LCL and to further develop and validate clinical measures as a part of an overall assessment tool to capture the response to treatment in LCL.

The overall aim of this work was to adopt a standardized and validated approach to assess agreed 140 clinical aspects of LCL and response to treatment in a measurable manner for use in clinical trials 141 142 and routine patient care which were then reflected in a practical tool. This paper describes identification through consensus of what to measure in LCL clinical trials (Core Outcome 143 Domains) and how to measure these aspects as well as the process involved in the development of 144 a clinical instrument which captures and measures the areas identified. Once developed, the 145 Leishmaniasis Core Outcome Measure Instrument for Localised Cutaneous Leishmaniasis 146 147 (LeishCOM LCL) was incorporated into a case report form (CRF) and the process of face and content validation was undertaken. Further comprehensive validation of the final outcome measure 148 instrument has been conducted through a clinical study. The results from this further validation 149 150 along with the methodology and detailed data will be reported in a separate manuscript (manuscript under preparation). 151

152 Methods

153 Ethical clearance

Ethical approval for the study was obtained from the University of Sri Jayewardenepura, Sri Lanka to develop a Core Outcome Measure Instrument aligned to HOME methodology and this included ethical approval to enroll patients for the face validity and future validation of any instrument developed (ERC 52/17).

158 Identification of Core Outcome Measures

Core Outcome Domains and Measures to assess agreed Domains were identified to inform an Outcome Measure Instrument (OMI; LeishCOM_LCL) for LCL. The HOME methodological framework was adopted using the following steps:

162 1. Development process; define scope and applicability.

A comprehensive literature review was carried out to identify publications that had identified COS 163 including domains, measures and instruments already aligned to LCL using PubMed, MEDLINE, 164 Cochrane library, COMET initiative, and COSMIN websites. This review identified the already 165 published work on harmonized outcome measures in LCL [16, 17, 25]. The principal investigators 166 laid down the conceptual framework. Formalizing the Core Outcome Domains for LCL had not 167 been established and this was therefore taken forward through a collaborative international 168 approach involving virtual discussions and e-consultations with stakeholder clinicians including 169 dermatologists and their teams who care for LCL from Sri Lanka, India, Brazil and the United 170 171 Kingdom.

172 2. Judgment process; define core set of outcome domains

A subsequent judgment process was then undertaken adopting the nominal group technique (NGT) 173 to reach a final consensual agreement on the set of Core Outcome Domains. The NGT approach 174 was performed by having face-to-face discussions at a workshop in March 2018 in Sri Lanka. The 175 NGT approach was selected to ensure that there was an opportunity to share clinical experience 176 and secure clear consensus among stakeholders. A multi-institutional, multi-disciplinary 177 stakeholder panel of international experts from Sri Lanka, India, Brazil, and the United Kingdom 178 comprising of dermatologists, general physicians and parasitologists were included along with a 179 moderator (n=20). For each Core Outcome Domain, a review of previous approaches to measure 180

the domain was considered [16, 17, 25]. During the workshop, items to measure the domains were 181 also evaluated and multiple rounds of discussions were carried out to secure agreement within the 182 panel of experts on "what to measure" which informed the final Core Outcome Domains as well 183 as "how to measure" the domains. Patient perspectives including clinical and psychological aspects 184 were captured by doing a field visit by the expert stakeholders one day before the NGT meeting to 185 a hospital-based dermatology clinic in a LCL endemic area (Hambantota) in Sri Lanka and had 186 face-to-face discussions with LCL patients. Also, the international clinicians taking care of their 187 LCL patients in other countries presented additional clinical and psychological perspectives within 188 their region to ensure that the most important patients' perspectives encountered in different 189 endemic areas were captured. 190

As noted previously, for each Core Outcome Domain, previous approaches on "how to measure the domains" were considered. The proposed items to measure the domains were then evaluated by multiple rounds until the same panel of experts reached a consensus. Once established, the construction of a novel clinical assessment tool "LeishCOM_LCL" for practical use in the field was developed. The various measures that informed the tool "LeishCOM_LCL" underwent multiple reviews during the period of reaching consensus and this included practical approaches to ensure that the assessments were conducted in a standardized manner.

Furthermore, during this process, a subjective judgment of the content validity was done by assessing: i) the degree to which no important items were missing (comprehensiveness), ii) the degree to which the items were correctly understood by the clinician and the patient (comprehensibility), and iii) relevance of the content of OMI for the assessment of healing of LCL lesions. The final version of the tool was incorporated into a case report form (CRF) for downstream application when assessing LCL patients in the field and during this process

underwent some face validity with more robust validation which will be described and reported ina separate manuscript.

206

207 3. Case Report Form (CRF) for data collection

The case report form (CRF) allowed data collection and validation of LeishCOM_LCL. It captures demographic details, reflects the core outcome domains, agreed outcome measurements, and includes scoring systems for the selected COS including visual analogue scores that capture clinician's and patient's perspectives. The CRF also includes two open-ended questions aimed at capturing some aspects of Health-related quality of life (HRQoL). Once established, the "LeishCOM_LCL" was subjected to an assessment of face validity [26, 27].

214 Face validity

Face and content validity of the core outcome instrument was assessed at the face-to-face meeting 215 as well as through multiple virtual feedback engagement between stakeholders. Further validation 216 217 was subsequently conducted by securing feedback from three independent consultant 218 dermatologists who were not involved in the development of the outcome measures. These consultants adopted the outcome measure instrument to assess five LCL patients in each of their 219 220 clinics (total number of patients (n) =15). As a result of their feedback, further and necessary 221 amendments to LeishCOM LCL and CRF were made. Although the authors appreciate that the 222 face validity can be subjective [26], they approached this including multiple rounds of virtual stakeholder engagement to ensure that the CRF measured what it was intended to measure [27]. 223

Further validation of LeishCOM_LCL was conducted through a subsequent longitudinal pilot study between March 2018 to March 2019 in a small cohort of 40 confirmed (parasitologically

- positive) LCL patients attending a dermatology clinic in Sri Lanka. Each patient was followed up,
- for a period of up to 6 months to validate the LeishCOM LCL tool. The methodology and positive
- results from this further study will be published elsewhere.

229 **Results**

230 Approach to the study

- 231 We used the HOME methodology to identify core outcome domains for the development of
- 232 LeishCOM_LCL as summarized in Fig 1. Following the development and judgment processes
- assessment of "Clinical Cure" was recognized as the overarching "General Concept". The Core
- Outcome Domains identified during the development and judgment process are given in Table 1.

Step 1: Define scope and applicability of identification of core outcome domains and a set of core outcome sets for LCL

23

Extensive literature review (MEDLINE, Cochrane library, COMET initiative, and COSMIN websites) e-consultation with expert stakeholders

₽

Step 2: Formalization and finalizing of a set of core outcomes to capture the domains

E-consultation & Stakeholders meeting adhering to NGT

Step 3: Development of a set of Core Outcome Measures to capture the COS

Identification and recommendation of COMI at NTG meeting

	Stage 1	Stage 2	Stage 3		
Task	Identification of all previously used		Determining which instruments are good enough to include in the CRF and LeishCOM_LCL and apply downstream in a clinical setting and subject to validation		
	instruments in LCL	of the instrument	Evaluation of contents of the OMERACT Filter		
Methodology	Expert opinion by e-consultation and MGT 				
			reliability) and sensitivity to change was assessed with the Treatment effect score and Subjective assessments; sum of palpability score and VASi, and Sequelae assessment score. *Feasibility was assessed by assessing the Time taken to apply the tool, Cost and Interpretability of the tool		
Output	Preparation of a list of domains and instruments [8-12, 16]	Summarized the results and arrived at consensus by e-consultation			
		and NGT meeting			

Fig 1. Summary of development stage of core set of outcomes in LeishCOM_LCL to each

Core Outcome Domains. Stage 1-3 in accord with HOME roadmap are described. *Assessed in the Validation process. #described in detail in results section. COMI: Core outcome measure instrument, CRF: case report form, HRQoL: Health Related Quality of Life, LCL: Localized cutaneous leishmaniasis, NGT: nominal group technique, VASi: Visual analogue score investigator, VASp: Visual analogue score patient.

242 Table 1. The core outcome domains were established based on consensus

	Identified Core Outcome Domains
1	Signs (Objective and Subjective assessments for localized disease/selected lesions)
2	Treatment efficacy
3	Treatment impact
4	Clinical sequelae (scarring & pigment) assessment
5	HRQoL

243 Measuring the core outcome domains

As previously described, a review of previous instruments or approaches to measure the domains was thoroughly considered. This identified that there was a paucity of measures used for LCL assessment. Therefore, each domain was discussed in detail and a standardized approach to assessing each domain was agreed on the understanding that this may require further development in the future.

249 1. Signs:

250 In the signs domain, to assess the primary efficacy endpoint; re-epithelialization (surface area of

the ulcer) and induration, the methods described by Olliaro et al. 2013 [16] were adopted to assess

the flattening of the elevated edge of the ulcerated lesions. Furthermore, a new palpability score was developed to assess both the ulcerated and non-ulcerated lesions and included in the assessment. Since erythema was not appreciated as a reliable or reproducible sign in skin of colour and pain was not considered as a universal symptom of LCL by the stakeholders, there was agreement not to measure erythema and pain. However, a free text space was provided in the CRF to record any additional signs and symptoms not captured by the agreed assessment.

258 2. Treatment efficacy

Reduction of lesion size (re-epithelialization in an ulcerated lesion) and reduced palpability defined as flattening / reduced induration of lesions were agreed as the parameters to measure the "Treatment efficacy" domain. Erythema was not considered a reliable measure of treatment efficacy and scars and pigmentation were noted to be important sequelae which were considered in a separate domain. Table 2 outlines the clinical features for assessment as efficacy measures that were agreed through consensus at the NGT face-to-face meeting.

265	Table 2: Cons	ensus about the	important	primary c	linical ef	ficacy me	easures were:

Primary clinical efficacy measure	Consensus arrived at
Re-epithelialization for ulcerated	ulcer surface area should be the primary efficacy endpoint
lesions	whenever possible.
Flattening of non-ulcerated lesions	for non-ulcerated lesions, area of induration should be used to
	measure treatment efficacy
Absence of induration	is a valuable efficacy measure but acknowledged as difficult to
	standardize

Overall erythema	was thought not sufficiently reliable to act as a measure of
	treatment efficacy especially in skin of colour.
Presence of scars and pigmentation	were recognized as important sequelae that required
	assessment/grading as part of a separate domain.

266

267 3. Treatment Impact

268 The treatment impact domain was recorded on each day of assessment by capturing the perception269 by both the investigator and the patient on a visual analogue score.

270 *4. Clinical Sequelae*

Pigmentary change (Hypo/hyper) and scarring (atrophic or hypertrophic) were recognized as the
parameters to capture for the clinical sequelae assessment domain. It was noted that either hypo or
hyperpigmentation could result from LCL and scars could be either atrophic or hypertrophic.
Therefore, all 4 changes were considered as clinical areas suitable for rating.

275 *5. HRQoL*

The impact of the HRQoL had not been previously considered in LCL and therefore two openended questions were included as a preliminary step to try and capture the most important aspects for the patient with a view to informing a novel tool at a later date. It was decided to include openended questions to make it easy and straightforward for the patient to respond and to capture the most important aspect of thoughts originated by the patient. This would further ensure that clinicians recognize patient's problems and consider these in patient management.

283 Generation of the Case Report Form (S Appendix 1).

A Case Report Form (CRF) was generated to document the demographic details and reflect the 284 285 agreed COS (Core Outcome Domains and Measurements) in each patient. The CRF contained a cover page noting the document category, code, title of the CRF, approved version, sponsor, date 286 of release, authorization from the Principal Investigator, and a table of contents to guide the user. 287 The next two pages of the CRF contained instructions for the user on individual items. Written as 288 well as diagrammatic and photographic instructions with clinical examples were provided for 289 measuring and assessing LCL to minimize any potential ambiguities. The rest of the pages 290 contained demographic details of the patient, enrollment particulars; details of obtaining consent, 291 slit skin smear and or punch biopsy details, relevant clinical history and examination details, 292 assessments at baseline, 4 weeks, 3 months, and 6 months from the onset of treatment, a summary 293 of scores over time, details on drug therapy, selected investigation results with dates, final 294 comments, and the investigator's signature with the date. The day of enrollment into the study was 295 296 taken as the "Baseline". Each time point was calculated from the Baseline. After several further rounds of feedback and revisions from experts as described in Methods, the 14th Version of the 297 CRF with clinical score was agreed as the final consensus version (S Appendix 1). 298

299

300 Capture of Signs domain (Objective and Subjective assessments)

301

a) Guidelines for selection of lesion to follow up and validation of OMIs

In the context of the study, as patients may have more than one lesion of LCL, guidelines were provided in the CRF to select an "index lesion" to be used throughout the period of clinical assessment. The index lesion represented a recent onset, clinically typical looking localised CL

lesion which was confirmed with positive parasitology. Each type of lesion was well described 305 (Supplementary Table 1). There was opportunity for the investigator to report "Any other atypical 306 307 lesions" on the CRF during examination (CRF Section 5.1.14). A further Section 5.1.15 in the CRF captured "Patient reported symptoms e.g. pain, loss of function etc." This was to build up in 308 the future if any useful signs were reported by the patient during the validation process. 309 The anatomical location of the lesion was identified on a body diagram. A space was provided to record 310 the biopsy site if taken. It was made compulsory to have a laboratory confirmed diagnosis (either 311 the presence of *Leishmania* amastigote in a slit skin smear/biopsy and histology or positive PCR) 312 to enroll patients during the downstream application of CRF on patients in the validation process 313 of LeishCOM LCL. 314

315 Outcome measurement instrument for signs

Objective assessment (lesion measurements with a ruler & ball-point pen) (S Fig 1 & 2) was described for ulcerated lesions as recommended by the previous harmonised guidance paper [16]. Both size of the ulcer and palpability of the induration were taken into consideration. As the panel perceived that palpability was an important feature of disease activity, a newly developed subjective assessment (a palpability score of 0,3,6,9) was described for both non-ulcerated and ulcerated lesions (0=flat, 9=severly raised) (Tables 3 & 4). Schematic images and/or photos alongside descriptions were used to standardise the assessment.

324 Table 3. Description of the palpability score for non-ulcerated lesions*

Category	Score	Description (by clinical evaluation)
Flat	0	Not Palpable
Mildly raised	3	Slightly elevated on palpation
		(whole lesion < 2mm raised from normal skin)
Moderately raised	6	Moderately elevated on palpation
		(whole lesion \geq 2-5 mm raised from normal skin)
Severely raised	9	Significantly raised on palpation and visibly elevated from the skin
*D 1 1 1	1 1 .	(whole lesion \geq 5mm raised from normal skin)

*Palpating the whole lesion in non-ulcerated lesions; Ball-point pen method (S Fig 2 [16]).

326

327 Table 4. Description of the palpability score based on the edge for ulcerated lesions*

Category	Score	Description (by clinical evaluation)
Flat	0	Not Palpable
Mildly raised	3	Slightly elevated on palpation
		(edge of the lesion < 2mm raised from normal skin)
Moderately raised	6	Moderately elevated on palpation
		(edge of the lesion \geq 2-5 mm raised from normal skin)
Severely raised	9	Significantly raised on palpation and visibly elevated from the skin.
		(edge of the lesion \geq 5 mm raised from normal skin)

328 * Instructions: for ulcerated lesions measure by palpating the "edge" of the ulcerated lesion.

329

330 Capture of "Treament Efficacy" domain

331 *Treatment effect score*

"Treatment Effect Score" was assessed at week 4 and at 3 & 6 months from initiation of treatment. 332 333 Since there are no specific guidelines on designing numerical scores, and different numerical scores have been used successfully to predict clinical outcomes [28], the clinicians present at the 334 NGT meeting agreed to rate the "Treatment Efficacy" with scores of 12, 9, 6, 3, 0; a score of 335 "12" was rated for no improvement and "0" for complete clinical cure. The Treatment Effect Score 336 mainly took into account the percentage change of the lesion size from baseline but also embraced 337 factors about re-epithelialization and inflammation at each assessment point in comparison with 338 baseline as a means of trying to prevent any ambiguity and ensure some consistency between raters 339 (Table 5). Although erythema was considered as "not sufficiently reliable to act as a measure of 340 treatment efficacy especially in skin of colour", it was decided to include an assessment of 341 "inflammation" (using subjective assessment of erythema by clinical-eyeballing) when doing an 342 Investigator Global assessment of the overall Treatment Effect Score as acute inflammation is 343 344 known to subside/disappear with wound healing [29]. This was combined with other anticipated features expected with therapeutic resolution of a lesion. 345

347 Table 5. Treatment effect score: Description of Investigator Global Assessment of an active

348 disease post-treatment

Score	Expected features	Allocate Score
12	No improvement. Lesion remained active, having the same characteristics, or becoming larger than prior to the start of treatment.	
9	Size of the lesion decreased 50% in comparison with the initial lesion, with fewer inflammatory signs* and discrete re-epithelialization (Size: diameter, length & width)	
6	Size of the lesion decreased between 50–90% in comparison with the initial lesion, and left few inflammatory signs*	
3	Size of the lesion decreased more than 90%, with re-epithelialization and very little inflammation*	
0	Complete re-epithelialization with a characteristic scar and no inflammation. Active disease settled	

³⁴⁹ *Inflammatory signs: erythema by clinical-eyeballing and having anticipated features expected

350 with therapeutic resolution of a lesion

351 Capture of "Treatment Impact" Domain

352 *Treatment impact score*

353 Visual Analogue Score (VAS)

To measure the impact of the treatment on the "skin problem" at the time of assessment a Visual

Analogue Score (VAS) ranging from 0 - 10 (0="completely clear skin", 10="severely affected"

skin") was described for both investigator (VASi) and patient (VASp) (CRF Section 6.3).

357 Patients and investigators were asked to consider how they would score the skin problem on the

- 358 day of assessment starting at baseline and after commencing treatment. Options were provided
- 359 for the investigator and the patient to put a mark on the line to indicate how adversely they
- perceived the skin was affected on the day of the assessment (at Baseline, 4 weeks, 3 months & 6

361	months from the onset of treatment). The	line of a VAS is 10cm in length and a score is allocated
362	according to the nearest whole cm (Fig 2)	
363		
364	Visual Analogue Score; Investigator's	Score (VASi)
365	How would you score this skin probler	n from 0-10 today?
366	0	10
367	Completely Clear	Severely Affected Skin
368 369	Visual Analogue Score; Patient's Scor	e (VASp)
370 371	How would you score your skin proble	em from 0-10 today?
372	0	10
373	Completely Clear	Severely Affected Skin
374		
375	Fig 2. Visual analogue score of the invest	igator (VASi) and patient (VASp). Each line was 10
376	cm long. Each score is to be allocated acc	ording to the nearest whole cm.
377	Capture of Clinical sequelae (scarring &	pigment) assessment domain
378	As sequelae including scarring and pigme	ent changes are a common occurrence from LCL, a new

379 Investigator Global Sequelae Assessment score was developed which consisted of "pigment

380 change, atrophic scars, and hypertrophic/keloid scars". Each of these items was rated from 0-3. The aim was to establish the frequency of development of sequelae and also to try and assess 381 382 whether earlier effective therapy might reduce the likelihood of sequelae. The investigator is asked to allocate a subjective score to the sequelae assessment. The scoring of pigmentation and scarring 383 was discussed in detail at the NGT judgment process, and it was decided to compare the colour 384 change in the lesion and the surrounding area of the lesion with the opposite unaffected side of the 385 body. Furthermore, photographs taken at the field visit were examined in detail at the NTG meeting 386 and scores ranging from 0-3 were allocated for pigment change by consensus (Table 6, and S Fig 387 3 & 4). Scarring was decided to be assessed by palpation and by close clinical examination (Table 388 6, and S Fig 5 & 6). 389

390 Table 6. Investigator Global Assessment of i & ii) Pigment change iii) Atrophic scars iv)

Score (0-3)	Score (0-3) Pigment Change (Hyperpigmentation)		
Category	Score	Description	
	0	No hyperpigmentation	
	1	Mild hyperpigmentation	
	2	Moderate hyperpigmentation	
	3	Severe hyperpigmentation	
Score (0-3)	Pigment	Change (Hypopigmentation)	
Category	Score	Description	
	0	No hypopigmentation	
	1	Mild hypopigmentation	
	2	Moderate hypopigmentation	
	3	Severe hypopigmentation	
Score (0-3)	Atrophic	scars	·
Category	Score	Description	
Clear	0	No scar visible or detectable on palpation	
Mild	1	Minimal atrophic scarring – little change on palpation	
Moderate	2	Atrophic scarring with textural changes of skin	
Severe			

391 Hypertrophic/ Keloid scars

Score (0-3) Hypertrophic / Keloid scars				
Category	Score	Description		
Clear	0	No scar visible or detectable on palpation		
Mild	1	Minimal hypertrophic scarring - some palpable change		
Moderate	2	Palpable scarring with textural changes of the skin		
Severe	3	Mutilating scar (with underlying structural involvement)		
TOTAL SCORE				

392

393 Summarizing the scores of the LeishCOM_LCL

A table to summarize the subjective scores (palpability score & VASi & VASp) and sequelae assessment scores were included at the end of the clinical score (Table 7). The summary of scores is to be calculated by each investigator/rater at the end of the assessment at each time point and entered in the table (Table 7). These data will be used later for analysis and to arrive at conclusions during clinical trials or at routine treatment clinics (manuscript is being prepared in the completed validation stage).

400 Table 7. Summary of scores

SUBJECTIVE	SCORE
Palpability; Non-ulcerated lesions	(0-9)
Palpability; Ulcerated lesions	(0-9)
Visual Analogue; Investigator	(0-10)
Visual Analogue; Patient	(0-10)
TOTAL	
TREATMENT EFFECT	SCORE
Investigator Assessment	(0-12)
TOTAL	
SEQUELAE ASSESSMENTS	SCORE
Pigment Change; Hyperpigmentation	(0-3)
Pigment Change; Hypopigmentation	(0-3)
Atrophic Scars	(0-3)
Hypertrophic/Keloid Scars	(0-3)
TOTAL	

⁴⁰¹

402 Capture of Health-Related Quality of Life (HRQoL) domains

403 Studies examining HRQoL in LCL are limited and the published studies have not necessarily acknowledged negative impacts including those caused by treatment [30, 31]. Thus our OMI 404 405 incorporated two open-ended questions "How does your skin problem affect you?" and "What are the three worst aspects of having your skin problem?" The aim was to assess the patient's 406 perspectives with a view to adapting the tool or developing a relevant patient reported outcome 407 measure encompassing HRQoL assessment in the future. Information on the two open-ended 408 questions was gathered from patients and thematic analysis was carried out during the validation 409 process in the downstream application of the CRF in a dermatology clinic in Sri Lanka. 410 Psychological impact improved in line with treatment response over a 6 month period from 411 baseline, however, 30% of patients expressed psychological concerns as a result of sequelae such 412 413 as pigment changes and scarring (Full data and results will be published in a separate manuscript).

414 **Face Validity**

415 The face validity was established on parameters regarding appropriateness of grammar, clarity and 416 unambiguity of items, correct spelling of words, correct structuring of sentences, appropriateness, and adequacy of instruction on the instrument, structure of the instrument in terms of construction 417 418 and, appropriateness of difficulty level of the instrument for the participants, and reasonableness of items in relation to the purpose of the instrument [27]. The content was addressed following 419 feedback sent by the three consultant dermatologists by applying the OMI to five patients at each 420 421 of their clinics (total patient number (n=15)) were considered before finalizing and revisions were made by experts with 100% agreement. 422

Further positive results of validity testing of the LeishCOM_LCL has been established includingcriterion validity. The robust methodology and results from this will be published separately.

425 Discussion

This paper includes detailed development of a COS for LCL with identification of Core Outcome 426 427 Domains, measurement of the domains and a development of a subsequent OMI through adoption of stages 1, 2 & 3 of the HOME roadmap [19, 24]. This study was initiated as in-depth literature 428 review revealed the absence of a standardized and validated COS for LCL to assess response to 429 current and novel treatment measures in clinical trials and clinical practice across the globe. This 430 scarcity has led to an overall inability of comparison between trials and recommendations of best 431 of care of management for LCL patients [8]. There was only one study that described a few 432 harmonized outcome measures for use in LCL clinical trials [16] which informed our 433 LeishCOM LCL. Our study is the first to identify a set of Core Outcome Domains for LCL using 434 435 recognised and robust methodology in a standardized manner. The study has also included consideration of how to measure the agreed domains in LCL as a means of developing a core 436 outcome set for use in the assessment of LCL. These have informed an outcome measurement tool 437 438 for LCL (LeishCOM LCL). As no outcome measures have previously been agreed by broad consensus for each domain, our group has developed and suggested an approach for each domain 439 and incorporated these measures into a practical tool LeishCOM LCL. 440

The NGT adopted during the development stage of this study is a valid technique, representing an alternative to the Delphi methodology [24]. Participation at the NGT meeting provided opportunity for open dialogue with a moderator and provided time for clinical presentations and translation where necessary.

This novel tool captures and scores relevant objective and subjective clinical outcomes embracing active signs including sequelae and takes into account the perspectives of both the patient's and investigator's with respect to the healing process and treatment of LCL lesions. A visual analogue

score was used to capture both participants' and investigators' perspectives as VAS is known to 448 be a valid, reliable, and repeatable method of assessment of therapeutic response in other 449 450 dermatological diseases [32]. The validation process with the small cohort of patients showed that this tool LeishCOM LCL is reliable with a good face and content validity. This tool will also be 451 useful to assess cure rates, treatment failure, relapse rate and to assess the other case management 452 indicators described in the Manual for case management of cutaneous leishmaniasis in the WHO 453 Eastern Mediterranean Region [17]. Further criterion validity has been performed in a larger 454 cohort and the robust methodology and positive results secured will be published in a separate 455 manuscript. 456

In recent years HRQoL and patient-reported outcome (PROs) have been considered as a very 457 458 important part of ensuring a patient-centered approach in disease management [33]. Addressing HRQoL in a systematic manner was beyond the scope of this study. However, we recognize that 459 additional measures could further enhance the assessment of LCL particularly in respect of 460 461 capturing patient-reported outcomes and HRQoL. In LeishCOM LCL, two open-ended HRQoL questions "How does your skin problem affect you?" and "what are the worst aspects of having 462 your skin problem?" were used to capture patients' perceptions of having LCL and the issues they 463 face during prolonged treatment. We adopted this pragmatic approach in the first instance to try 464 and ensure the patient's perspective was recorded on paper. No previous study to date has 465 attempted to record/report these aspects. The results from this approach were analyzed during the 466 validation process and this highlighted the need to ensure adverse effects from treatments and 467 negative impacts of LCL are fully recognized when assessing this disease thus enabling a patient-468 469 focused and empathic approach to management (details are due for publication in a validation paper). The authors suggest that this work could help to inform the development of a more robust 470

PROM specific to LCL in the future and the authors appreciate that systematic qualitative research
with audio recordings would be helpful to expand upon this area with robust analysis.

473 The lack of a more diverse group of stakeholders including dermatologists from the Mediterranean region and Africa, patients from diverse geographic areas, and pharmaceutical industry 474 representation was another limitation in this study. However, the stakeholders involved 475 476 represented important endemic regions for LCL and the authors acknowledge that further improvement and fine-tuning of this OMI may be achieved by including further stakeholders from 477 other LCL endemic regions with a global representation and further individual outcome measures 478 may need to be developed for each Core Outcome Domain, particularly relating to HRQoL. The 479 team also appreciate further engagement with patients from each region as well as personnel from 480 481 the pharmaceutical industries and regulatory bodies could inform future discussions and adoption. Furthermore, it will be important in the future to assess whether, scarring and pigmentation should 482 remain a primary efficacy endpoint or secondary efficacy endpoint and how these might impact 483 HRQoL. Data analysis secured from the validation process will help to inform future 484 improvements and this approach will complete stage 4 & 5 of HOME methodology. 485

The quality assurance stage (Stages 4 & 5); validity, reliability, responsiveness, interpretability and feasibility of scoring and HRQoL had already been assessed in the newly developed LeishCOM_LCL tool by applying the OMI downstream in a dermatology clinic to a small cohort of patients (n=40) in Sri Lanka in accord with the HOME roadmap [24], COSMIN [34] and Guidance for Industry Patient-Reported Outcome Measures: Use in Medical Product Development to Support Labeling Claims, U.S. Department of Health and Human Services Food and Drug Administration Center 2009 [35]. This will be presented in a future manuscript.

In conclusion, the Core Outcome Domains i.e. what to measure in LCL have now been defined through a process of consensus. Agreement on how to measure the agreed Core Outcome Domains was secured following literature review and a multidisciplinary and international stakeholder meeting. The LeishCOM_LCL is the first OMI to be developed in a standardized manner to assess LCL and therefore provides potential for broad adoption for use in clinical trials and routine clinical settings.

499 Our future aim is to update the LeishCOM_LCL to reflect important views of patients when 500 collecting information and to consider developing a PROM specific to LCL. A specific PROM 501 should ensure adverse effects from treatments as well as the negative impacts of LCL are captured 502 when assessing this disease thus enabling a patient-focused and empathic approach to 503 management.

504 **Conflicts of interest:**

505 The authors declare that there are no conflicts of interest.

Funding: Medical Research Council - Global Challenges Research Fund (MRC-GCRF)
MR/P024661/1. Sponsors or funders (other than the named authors) played no role in study design.
data collection and analysis, decision to publish or preparation of the manuscript.

Acknowledgments: We thank and acknowledge the Sri Lanka College of Dermatologists for
giving their immense support during the development and validation process of this OMI

511 References

World Health Organization [Internet]. Leishmaniasis [cited 2023 June 27]. Available
 from: <u>https://www.who.int/news-room/fact-sheets/detail/leishmaniasis</u>.

514	2.	Scorza BM, Carvalho EM, Wilson ME. Cutaneous Manifestations of Human and
515		Murine Leishmaniasis. Int J Mol Sci. 2017;18: 1296. doi: 10.3390/ijms18061296.
516		PMID: 28629171.
517	3.	Reithinger R, Dujardin JC, Louzir H, Pirmez C, Alexander B, Brooker S. Cutaneous
518		leishmaniasis. Lancet Infect Dis. 2007;7: 581-96. doi: 10.1016/S1473-3099(07)70209-
519		8. PMID: 17714672.
520	4.	Garza-Tovar TF, Sacriste-Hernández MI, Juárez-Durán ER, Arenas R. An overview of
521		the treatment of cutaneous leishmaniasis. Fac Rev. 2020;22: 28. doi: 10.12703/r/9-28.
522		PMID: 33659960.
523	5.	Goyonlo VM, Vosoughi E, Kiafar B, Nahidi Y, Momenzadeh A, Taheri AR. Efficacy
524		of intralesional amphotericin B for the treatment of cutaneous leishmaniasis. Indian J
525		Dermatol. 2014;59: 631. doi: 10.4103/0019-5154.143571. PMID: 25484415.
526	6.	Mosimann V, Neumayr A, Paris DH, Blum J. Liposomal amphotericin B treatment of
527		Old World cutaneous and mucosal leishmaniasis: A literature review. Acta Trop.
528		2018;182: 246-250. doi: 10.1016/j.actatropica.2018.03.016. PMID: 29550282.
529	7.	WHO Expert Committee on the Control of the Leishmaniases (Eds). WHO Technical
530		Series 949: Control of the leishmaniases. World Health Organization, Geneva; 2010.
531	8.	López-Carvajal L, Vélez I, Arbeláez MP, Olliaro P. Eligibility criteria and outcome
532		measures adopted in clinical trials of treatments of cutaneous leishmaniasis: systematic
533		literature review covering the period 1991-2015. Trop Med Int Health. 2018;23: 448-
534		475. doi: 10.1111/tmi.13048. PMID: 29524291.

- González U, Pinart M, Reveiz L, Alvar J. Interventions for Old World cutaneous
 leishmaniasis. Cochrane Database Syst Rev. 2008;8: CD005067. doi:
 10.1002/14651858.CD005067.pub3. PMID: 18843677.
- 53810.González U, Pinart M, Rengifo-Pardo M, Macaya A, Alvar J, Tweed JA. Interventions539for American cutaneous and mucocutaneous leishmaniasis. Cochrane Database Syst
- 540 Rev. 2009;15: CD004834. doi: 10.1002/14651858.CD004834.pub2. PMID: 19370612.
- Heras-Mosteiro J, Monge-Maillo B, Pinart M, Lopez Pereira P, Reveiz L, GarciaCarrasco E, et al. Interventions for Old World cutaneous leishmaniasis. Cochrane
 Database Syst Rev. 2017;11: CD005067. doi: 10.1002/14651858.CD005067.pub4.
 PMID: 29149474.
- 545 12. Pinart M, Rueda JR, Romero GA, Pinzón-Flórez CE, Osorio-Arango K, Silveira Maia-Elkhoury AN, et al. Interventions for American cutaneous and mucocutaneous 546 leishmaniasis. 547 Cochrane Database Syst Rev. 2020;8: CD004834. doi: 548 10.1002/14651858.CD004834.pub3. PMID: 32853410.
- Ranawaka RR, Weerakoon HS. Randomized, double-blind, comparative clinical trial
 on the efficacy and safety of intralesional sodium stibogluconate and intralesional 7%
 hypertonic sodium chloride against cutaneous leishmaniasis caused by L. donovani. J
 Dermatolog Treat. 2010;21: 286-93. doi: 10.3109/09546630903287445. PMID:
 20438389.
- 14. Ranawaka RR, Weerakoon HS, Opathella N. Liquid nitrogen cryotherapy on
 Leishmania donovani cutaneous leishmaniasis. J Dermatolog Treat. 2011;22: 241-5.
 doi: 10.3109/09546631003762654. PMID: 20818996.

- 15. Refai WF, Madarasingha NP, Sumanasena B, Weerasingha S, De Silva A,
 Fernandopulle R, et al. Efficacy, Safety and Cost-Effectiveness of Thermotherapy in
 the Treatment of Leishmania donovani-Induced Cutaneous Leishmaniasis: A
 Randomized Controlled Clinical Trial. Am J Trop Med Hyg. 2017;97: 1120-1126. doi:
 10.4269/ajtmh.16-0879. PMID: 28820681.
- 562 16. Olliaro P, Vaillant M, Arana B, Grogl M, Modabber F, Magill A, et al. Methodology
 563 of clinical trials aimed at assessing interventions for cutaneous leishmaniasis. PLoS
 564 Negl Trop Dis. 2013;7: e2130. doi: 10.1371/journal.pntd.0002130. PMID: 23556016.
- 565 17. WHO Regional Office for Eastern Mediterranean. Manual for case management of
 566 cutaneous leishmaniasis in the WHO Eastern Mediterranean Region. WHO Regional
 567 Publications, Mediterranean Series 35;2014.
- 568 18. Webbe J, Sinha I, Gale C. Core Outcome Sets. Arch Dis Child Educ Pract Ed.
 569 2018;103: 163-166. doi: 10.1136/archdischild-2016-312117. PMID: 28667046.
- Schmitt J, Spuls PI, Thomas KS, Simpson E, Furue M, Deckert S, et al; HOME
 initiative collaborators. The Harmonising Outcome Measures for Eczema (HOME)
 statement to assess clinical signs of atopic eczema in trials. J Allergy Clin Immunol.
 2014 ;134: 800-7. doi: 10.1016/j.jaci.2014.07.043. PMID: 25282560.
- Richardson E, McEwen A, Newton-John T, Crook A, Jacobs C. Incorporating patient
 perspectives in the development of a core outcome set for reproductive genetic carrier
 screening: a sequential systematic review. Eur J Hum Genet. 2022;30: 756-765. doi:
 10.1038/s41431-022-01090-1. PMID: 35347269.
- 578 21. Fredriksson T, Pettersson U. Severe psoriasis--oral therapy with a new retinoid.
 579 Dermatologica. 1978;157: 238-44. doi: 10.1159/000250839. PMID: 357213.

- Hanifin JM, Baghoomian W, Grinich E, Leshem YA, Jacobson M, Simpson EL. The
 Eczema Area and Severity Index-A Practical Guide. Dermatitis. 2022;33: 187-192. doi:
 10.1097/DER.00000000000895. PMID: 35594457.
- 23. Hamzavi I, Jain H, McLean D, Shapiro J, Zeng H, Lui H. Parametric modeling of 583 narrowband UV-B phototherapy for vitiligo using a novel quantitative tool: the Vitiligo 584 Area Scoring Index. Arch Dermatol. 2004; 140:677-83. doi: 585 10.1001/archderm.140.6.677. PMID: 15210457. 586
- Schmitt J, Apfelbacher C, Spuls PI, Thomas KS, Simpson EL, Furue M, et al. The
 Harmonizing Outcome Measures for Eczema (HOME) roadmap: a methodological
 framework to develop core sets of outcome measurements in dermatology. J Invest
 Dermatol. 2015;135: 24-30. doi: 10.1038/jid.2014.320. PMID: 25186228.
- 591 25. Olliaro P, Grogl M, Boni M, Carvalho EM, Chebli H, Cisse M, et al. Harmonized
 592 clinical trial methodologies for localized cutaneous leishmaniasis and potential for
 593 extensive network with capacities for clinical evaluation. PLoS Negl Trop Dis.
 594 2018;12: e0006141. doi: 10.1371/journal.pntd.0006141. PMID: 29329311.
- 595 26. Downing SM. Face validity of assessments: faith-based interpretations or evidence596 based science? Med Educ. 2006;40: 7-8. doi: 10.1111/j.1365-2929.2005.02361. x.
 597 PMID: 16441314.
- 598 27. Desai S and Patel N. ABC of Face Validity for Questionnaire. Int. J. Pharm. Sci. Rev.
 599 Res. 2020;65: 164-168. doi: 10.47583/ijpsrr. 2020.v65i01.025.
- Bakhtavar HE, Bagi HRM, Rahmani F, Nia SK, Ettehadi A. Clinical Scoring Systems
 in Predicting the Outcome of Acute Upper Gastrointestinal Bleeding; a Narrative
 Review. Emerg (Tehran). 2017;5: e36. PMID: 28286843.

- 603 29. Guo S, Dipietro LA. Factors affecting wound healing. J Dent Res. 2010;89: 219-29.
 604 doi: 10.1177/0022034509359125. PMID: 20139336.
- 30. Ranawaka RR, Weerakoon HS, de Silva SH. The quality of life of Sri Lankan patients
 with cutaneous leishmaniasis. Mymensingh Med J. 2014;23: 345-51. PMID:
 24858165.
- Refai WF, Madarasingha NP, Sumanasena B, Weerasingha S, Fernandopulle R,
 Karunaweera ND. Cutaneous leishmaniasis in Sri Lanka: effect on quality of life. Int J
 Dermatol. 2018;57: 1442-1446. doi: 10.1111/ijd.14240. PMID: 30246447.
- 32. Pedersen CB, McHorney CA, Larsen LS, Lophaven KW, Moeller AH, Reaney M.
 Reliability and validity of the Psoriasis Itch Visual Analog Scale in psoriasis vulgaris.
 J Dermatolog Treat. 2017;28: 213-220. doi: 10.1080/09546634.2016.1215405. PMID:
 27454156.
- 33. Philpot LM, Barnes SA, Brown RM, Austin JA, James CS, Stanford RH, et al. Barriers
 and Benefits to the Use of Patient-Reported Outcome Measures in Routine Clinical
 Care: A Qualitative Study. Am J Med Qual. 2018;33: 359-364. doi:
 10.1177/1062860617745986. PMID: 29258323.
- 619 34. Prinsen CA, Vohra S, Rose MR, Boers M, Tugwell P, Clarke M, et al. How to select
 620 outcome measurement instruments for outcomes included in a "Core Outcome Set" a
 621 practical guideline. Trials. 2016;17: 449. doi: 10.1186/s13063-016-1555-2. PMID:
 622 27618914.
- 35. U.S. Department of Health and Human Services FDA Center for Drug Evaluation and
 Research; U.S. Department of Health and Human Services FDA Center for Biologics
 Evaluation and Research; U.S. Department of Health and Human Services FDA Center

626	for Devices and Radiological Health. Guidance for industry: patient-reported outcome
627	measures: use in medical product development to support labeling claims: draft
628	guidance. Health Qual Life Outcomes. 2006; 4:79. doi: 10.1186/1477-7525-4-79.
629	PMID: 17034633.

630


632 Supplementary tables

633 S1 Table. Guidelines for clinical categorization of the Index Lesion*


Presenting sign(s): Please indicate which of the following. clinical features are evident and the number of lesions at the time of presentation and if possible, the duration of the lesion (s).					
5.1.1 Recent onset macule (circumscribed change in the					
color of skin that is flat on palpation – (excludes scarring and post inflammatory					
pigmentary change) 5.1.2 Papule (≤5mm diameter, palpable solid elevation)					
5.1.3 Nodule (>5 mm diameter, palpable elevation)					
5.1.4 Plaque (flat topped with diameter greater than its					
height)					
Ulcerative change					
5.1.5 Dry ulcer (destruction of epidermis of skin with central					
crusting/scaling)					
5.1.6 Wet ulcer (destruction of epidermis of skin with wet					
exudates)					
5.1.7 Nodular ulcerative (> 5mm diameter, palpable					
elevation with central ulceration)					
Other features associated with acute lesion(s)					
5.1.8 Satellite lesions					
5.1.9 Halo pigmentation					

- *An active lesion of most recent onset which was parasitologically confirmed has to be selected
- as an "index lesion" to be assessed throughout the study from one time point to another.

637 Supplementary Figures




644 **S Fig 1. Instructions to measure the diameters of an ulcerated lesion**. Measure the largest 645 diameter of the ulcerated area [D1] and then select the largest diameter that is perpendicular to 646 the original measurement taken [D2]. If adherent crust evident, assess the 2 largest diameters of 647 the crusted area in the same way [8]. AE: Elevated active edge of the lesion.




653 S Fig 2. Instructions to measure the diameters of the indurated area of a non-ulcerated 654 lesion. Identify the widest diameter of the lesion and draw two lines up to the edge of the lesion 655 in line with the largest diameter [A] and then measure the distance between the two lines [B]. 656 Similarly find the largest diameter that is perpendicular to the original measurement taken as 657 above.

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.




- 662 S Fig 3. Grading of hyperpigmentation during the NGT meeting. A: no hyperpigmentation,
- B: mild hyperpigmentation, C: moderate hyperpigmentation, D: severe hyperpigmentation. NGT:
- 664 Nominal group technique

665




- 672
- 673 S Fig 4. Grading of hypopigmentation during the NGT meeting. A: no hypopigmentation, B:
- 674 mild hypopigmentation, C: moderate hypopigmentation, D: severe hypopigmentation.



675

- 676 **S Fig 5. Grading of atrophic scarring during the NGT meeting.** A: no atrophic scarring, B:
- 677 mild atrophic scarring, C: moderate atrophic scarring, D: severe atrophic scarring.

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



- 686 scarring, B: mild hypertrophic scarring, C: moderate hypertrophic scarring, D: severe
- 687 hypertrophic scarring.

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

CASE REPORT FORM FOR LOCALISED CUTANEOUS LEISHMANIASIS

LeishPathNet

Towards a global research network for the molecular pathological stratification of leishmaniasis

Document Category:	Case Report Form
Code:	LEISHPATHNET_CRF_001
Title:	Localised Cutaneous Leishmaniasis
Version:	14
Sponsor:	University of York
Release Date:	19 June 2018

Authorised by	Signature	Date
Paul Kaye, Project Lead, Professor of Immunology		19.06.2018

Table of Contents

Instructions for use	(Pages 2 - 3)
Demographics and details of presentation	(Pages 4 - 6)
Assessments	
Baseline	(Pages 7 - 11)
• 4 weeks	(Pages 12 - 15)
• 3 months	(Pages 16 - 19)
• 6 months	(Pages 20 - 23)
Summary scores over time	(Page 24)
Drug therapy	(Pages 25 - 26)
Final comments and investigator signature	(Page 27)

1. INSTRUCTIONS FOR MEASURING AND ASSESSING LOCALISED CUTANEOUS LEISHMANIASIS

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. DEFINING LOCALISED CUTANEOUS LEISINMAN as the author/funder a CC-BY 4.0 International license.

Include patients with up to 5 lesions. Please take a photo of the lesions as per SOP for photography.

INSTRUCTIONS FOR IDENTIFYING LESIONS AND TAKING BIOPSIES


Clearly identify which lesions will be assessed at each visit and where biopsies have been taken on the figures in the CRF

Provide a description of any lesion(s) biopsied and / or being assessed at each visit in the table below the figures as indicated.

OBJECTIVE ASSESSMENTS FOR LOCALISED DISEASE/SELECTED LESIONS


a) Ulcer size

Measure the largest diameter of the ulcerated area [D1] and then select the largest diameter that is perpendicular to the original measurement taken [D2]. If adherent crust evident, assess the 2 largest diameters of the crusted area in the same way [16].



b) Area of induration of the lesion

Identify the widest diameter of the lesion and draw two lines up to the edge of the lesion in line with the largest diameter and then measure the distance between the two lines. Similarly find the largest diameter that is perpendicular to the original measurement taken as above.



SUBJECTEVEXASSES6MENTS FOR DOCALISED DISEASE/SELECTED MESIONS sted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

For **non-ulcerated** areas measure by palpating the whole lesion and indicate a palpability score as below

Category	Score	Description (by clinical evaluation)	
Flat	0	Not Palpable	
Mildly raised	3	Slightly elevated on palpation	
		(whole lesion < 2mm raised from normal skin)	
Moderately raised	6	Moderately elevated on palpation	
		(whole lesion \geq 2-5 mm raised from normal skin)	
Severely raised	9	Significantly raised on palpation and visibly elevated from the skin	
		(whole lesion \geq 5mm raised from normal skin)	

For <u>ulcerated lesions</u> measure by palpating the EDGE of the lesion

Category	Score	Description (by clinical evaluation)	
Flat	0	Not Palpable	
Mildly raised	3	Slightly elevated on palpation	
		(edge of the lesion < 2mm raised from normal skin)	
Moderately raised	6	Moderately elevated on palpation	- de la
		(edge of the lesion \geq 2-5 mm raised from normal skin)	ALC: CA
Severely raised	9	Significantly raised on palpation and visibly elevated from the skin.	1
		(edge of the lesion \geq 5 mm raised from normal skin)	

VISUAL ANALOGUE SCORE

Please ask healthcare professional **AND** the patient to put a mark on the line to indicate how badly they perceive the skin is affected **on the day of the assessment**. The line is 10cm and the score will be allocated according to the nearest whole cm. 0 represents clear skin and 10 represents the worse the skin can get.

TREATMENT EFFECT SCORES

Please indicate how much improvement there has been at visits 4 weeks, 3 months and 6 months

SEQUELAE ASSESSMENTS

Please score the various potential sequelae from 0-3

MEASURING HRQoL

Please ask patients two open ended questions, as indicated in the CRF.

DATA FOR CASE REPORT FORM FOR LOCALISED CUTANEOUS HIE ISHMANIASIBAY 28, 2024. The copyright holder for this preprint (which was not cortified by poor review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Towards a global research net work of the author/funder and the control of the author/funder and the control of t

Protocol No.

Patient's Reference Number:

Date:

1. Subject Demographics

1.1 Name:		sidential Address with <u>Cc</u> ing District)	ontact Number	
1.2 Date of Birth:	1.6	Education: Grade:	No schooling School education Graduate Postgraduate	
1.3 Gender: M F	1.7 Oc	cupation:		
1.4 OPD Registration Number:	1.8 Mo	onthly Family Income: (ir	local currency)	

2. Enrolment Particulars

2.1 Consent for Current Study Yes No	
2.2 Consent for Future Studies Yes No	
2.3 Subject Code : SL/IN/BR	2.5 Date/s of Punch Biopsy & Slit Skin Smear Collection:
2.4 Date of Entry in Study:	2.6 Photography Taken :Yes No
	Date: number/s*
	Date:number/s
	Date: number/s
	Date:number/s
	*specific number/s allocated to the photo/s

3. Medical History and Examination

3.1 Past History of Kala-azar/Visceral Leishmaniasis	
Yes No N/A	Date of onset (if known)
	Duration of Treatment
	Date of Cure (id known)

medRxiv preprint doi: https://c	loi.org/10.	1101/2024.	.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint
3.2 Any Other Relevant Med	ical Prol	Riems de a	.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint e author/funder, who has granted medRxiv a license to display the preprint in perpetuity. available under a CC-BY 4.0 International license.
•			
3.3 Drug History			Treatment Details (drugs with duration of therapy)
3.3.1 Previous Treatment for Yes No N/A		ar/ Visce	eral Leishmaniasis:
Yes No N/A			
3.3.2 Any Other Relevant Me	dicatio	n:	
3.4 Travel History (specify the	e countr	·y)	
3.5 General Examination	Yes	No	
3.5.1 Fever 3.5.2 Pallor			If yes, record temperature (°C/°F)
3.5.3 Lymphadenopathy			If yes, sites: cervical / axillary / inguinal / generalized
3.6 Abdominal Examination	Yes	No	Left / Right / Both
3.6.1 Hepatomegaly			If yes, how many cm below the R costal margin cm
3.6.2 Splenomegaly			If yes, how many cm below the L costal margin cm

4. SITES AND EXTENT OF DISEASE

Please indicate the site(s)/extent of the lesion(s) on the figure below; at time of recruitment

(ucc) (assult		
	the law	

Page 5 of 27

5. CLINICAB PRESENTATION:/lesion/characteristicsat/ecitinmentersion posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. *Definition of the "index lesion" - a legionate semanal outset, address address address address address address a

parasitologically to be assessed throughout the study from one time point to another.

Presenting sign(s): Please indicate which of the following	Presence of	Number of	Duration in
clinical features are evident and the number of lesions at	lesion types	lesions; tick	months (if less
the time of presentation and if possible the duration of the		relevant box	than one
lesion (s).			month in
			weeks)
5.1.1 Recent onset macule (circumscribed change in the	Yes No	1 2-5	
color of skin that is flat on palpation – (excludes			
scarring and post inflammatory pigmentary change)			
5.1.2 Papule (≤5mm diameter, palpable solid elevation)	Yes No	1 2-5	
5.1.3 Nodule (>5 mm diameter, palpable elevation)	Yes No	1 2-5	
5.1.4 Plaque (flat topped with diameter greater than its height)	Yes No	1 2-5	
Ulcerative change			
5.1.5 Dry ulcer (destruction of epidermis of skin with central crusting/scaling)	Yes No	1 2-5	
5.1.6 Wet ulcer (destruction of epidermis of skin with wet	Yes No	1 7 2-5	
exudates)			
5.1.7 Nodular ulcerative (> 5mm diameter, palpable	Yes No	1 2-5	
elevation with central ulceration)			
Other features associated with acute lesion(s)			
5.1.8 Satellite lesions	Yes No	1 2-5	
5.1.9 Halo pigmentation	Yes No	1 2-5	
Sequelae from resolved or resolving lesion(s)		· · · · · · · · · · · · · · · · · · ·	
5.1.10 Hyperpigmentation	Yes No	1 2-5	
5.1.11 Hypopigmentation	Yes No	1 2-5	
5.1.12 Atrophic Scarring	Yes No	1 2-5	
5.1.13 Hypertrophic or Keloid scarring	Yes No	1 2-5	
5.1.14 Any other atypical lesions – remarks			•
5.1.15 Patient reported symptoms e.g. pain, loss of function et	с.		


medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. LOCALISED CUTANEOUS LEISHMANIASIS measurements of the second s

6.1 Baseline biopsy and index lesion(s) for assessment

- a) Please indicate on the figure below the site(s) of any biopsy(ies) taken and mark with a letter e.g. A
- b) Draw the lesion(s) biopsied in the box and indicate where the biopsy has been taken (M= medial L = lateral)
- c) Indicate features of the lesion(s) biopsied in the table below
- d) Distinguish any index lesion(s) for assessment throughout the study from the biopsy sites on the figures, and mark with a different letter.

Niopsy site at baseline (front) A L		Bic M	opsy site at ba	seline (back) L
			2	
ریی کی Features of lesion(s) biopsied and under assessment. Please indicate	Lesion A	Lesion B	Lesion C	Lesion D
the clinical features of any lesion biopsied as well as any	Biopsy	Biopsy	Biopsy	Biopsy
other lesions undergoing assessment.	Y/N	Y/N	Y/N	Y/N
If possible please include the duration of the lesion (s).				
Macule (circumscribed change in the				
color of skin that is flat on palpation – (excludes scarring and post				
inflammatory pigmentary change)				
Papule (<5mm diameter, palpable solid elevation)				
Nodule (>5 mm diameter, palpable elevation)				
Plaque (flat topped with diameter greater than its height)				
Ulcerative change				
Dry ulcer (destruction of epidermis of skin with central				
crusting/scaling)				
Wet ulcer (destruction of epidermis of skin with wet exudates)				
Nodular ulcerative (>5mm diameter, palpable elevation with central				
ulceration)				
Other features associated with the lesion(s)		T	T	
Satellite lesions				
Halo pigmentation				
Hyperpigmentation				
Hypopigmentation				
Atrophic Scarring				
Atrophic Scarring Hypertrophic or Keloid scarring				
Atrophic Scarring				

6.2 OBJECRWEPASSESSIVIENTS dBASELINE 1/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.



Please Indicate Site	Size of the ulco pres 2 largest d	ent	Total Area mm ²	Area of induration 2 largest diameters Diameter 1 (mm) Diameter 2 (mm)		Total Area mm ²
	Diameter 1 (mm)	Diameter 2 (mm)	D1 x D2			D1 x D2

6.3 SUBJECTIVE ASSESSMENTS: BASELINE

Assessment using a palpability score

For **mulcerated** areas measure by palpating the whole lesion and indicate a palpability score, as described. (See page 3 for instructions.)

Score Allocated:

For <u>ulcerated lesions</u> measure by palpating the EDGE of the lesion and allocate a score, as described. (See page 3 for instructions.)

Score Allocated:

Score Allocated:

Visual Analogue Score; Investigator's Score (See page 3 for instructions)

How would you score this skin problem from 0-10 today?

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 6.4 TREATMENT EFFECT SCORES: BASELINE

Investigator's assessment of active disease post treatment Not required for Baseline visit

6.5 SEQUERAE ASSESSMENTS BASELINE 01/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Investigator Global Assessment of i & ii) Pigment change iii) Atrophic Scars iv) Hypertrophic/ Keloid scars

Score (0-3)	Pigment C	hange hyperpigmentation	Allocate Score
Category	Score	Description	
	0	No hyperpigmentation	
	1	Mild hyperpigmentation	
	2	Moderate hyperpigmentation	
	3	Severe hyperpigmentation	
Score (0-3)	Pigment C	hange hypopigmentation	
Category	Score	Description	
	0	No hypopigmentation	
	1	Mild hypopigmentation	
	2	Moderate hypopigmentation	
	3	Severe hypopigmentation	
Score (0-3)	Atrophic s	cars	
Category	Score	Description	
Clear	0	No scar visible or detectable on palpation	
Mild	1	Minimal atrophic scarring – little change on palpation	
Moderate	2	Atrophic scarring with textural changes of skin	
Severe	3	Deep atrophic / mutilating scar	
Score (0-3)	Hypertrop	hic / Keloid scars	
Category	Score	Description	
Clear	0	No scar visible or detectable on palpation	
Mild	1	Minimal hypertrophic scarring - some palpable change	
Moderate	2	Palpable scarring with textural changes of the skin	
Severe	3	Mutilating scar (with underlying structural involvement)	
TOTAL SCO			

6.6 HRQoL: BASELINE

- 1) How does your skin problem affect you?
- 2) What are the 3 worst aspects of having your skin problem?

 medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 6.7 SUMMARY OF SCORES: BASELINE

SUBJECTIVE	SCORE
Palpability; non-ulcerated lesions	(0-9)
Palpability; ulcerated lesions	(0-9)
Visual Analogue; investigator	(0-10)
Visual Analogue; patient	(0-10)
TOTAL	
SEQUELAE ASSESSMENTS	SCORE
Pigment Change; hyperpigmentation	(0-3)
Pigment Change; hypopigmentation	(0-3)
Atrophic Scars	(0-3)
Hypertrophic/Keloid Scars	(0-3)
TOTAL	

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. **7. LOCALISED CUTANEOUS LEISHMANIASIS**: madA/ Text Sole under a CC-BY 4.0 International license.

7.1. FOUR WEEK BIOPSY AND INDEX LESION(S) FOR ASSESSMENT

- a) Please indicate on the figure below the site(s) of any biopsy(ies) taken and mark with a letter e.g. A
- b) Draw the lesion(s) biopsied in the box and indicate where the biopsy has been taken (M= medial L = lateral)
- c) Indicate features of the lesion(s) biopsied in the table below
- d) Distinguish any index lesion(s) for assessment throughout the study from the biopsy sites on the figures, and mark with a different letter.

Biopsy site at baseline (front) M L			Biop	osy site at base	line (back) L
Features of lesion(s) biops	ied and under assessment. Plea	se indicate Lesion A	Lesion B	Lesion C	Lesion D

Features of lesion(s) biopsied and under assessment. Please indicate	Lesion A	Lesion B	Lesion C	Lesion D
the clinical features of any lesion biopsied as well as any	Biopsy	Biopsy	Biopsy	Biopsy
other lesions undergoing assessment.	Y/N	Y/N	Y/N	Y/N
If possible please include the duration of the lesion (s).				
Macule (circumscribed change in the				
color of skin that is flat on palpation – (excludes scarring and post				
inflammatory pigmentary change)				
Papule (≤5mm diameter, palpable solid elevation)				
Nodule (>5 mm diameter, palpable elevation)				
Plaque (flat topped with diameter greater than its height)				
Ulcerative change				
Dry ulcer (destruction of epidermis of skin with central				
crusting/scaling)				
Wet ulcer (destruction of epidermis of skin with wet exudates)				
Nodular ulcerative (>5mm diameter, palpable elevation with central				
ulceration)				
Other features associated with the lesion(s)				•
Satellite lesions				
Halo pigmentation				
Hyperpigmentation				
Hypopigmentation				
Atrophic Scarring				
Hypertrophic or Keloid scarring				
Duration of lesion if known				
Any other features – remarks				

7.2. OBJECTHRE ASSESSMENTS OF INDEX LESION(S): 24 WEEKS4; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

Area of Ulcer and Induration. (See page 2 for instructions)



Please Indicate Site	pre	erated area if sent diameters	Total Area mm ²	Area of induration 2 largest diameters		Total Area mm ²	
	Diameter 1 (mm)	Diameter 2 (mm)	D1 x D2	Diameter 1 (mm)	Diameter 2 (mm)	D1 x D2	

7.3. SUBJECTIVE ASSESSMENTS: 4 WEEKS

Assessment using a palpability score

For **<u>non-ulcerated</u>** areas measure by palpating the whole lesion and indicate a palpability score, as described. See page 3 for instructions.

Score Allocated:

For <u>ulcerated lesions</u> measure by palpating the EDGE of the lesion and allocate a score, as described. See page 3 for instructions.

Score Allocated:	
------------------	--

Visual Analogue Score; Investigator's Score (See page 3 for instructions)

How would you score this skin problem from 0-10 today?

0 —

— 10

Completely Clear

Severely Affected Skin

Score Allocated:

Visual Analogue Score; Patient's Score (See page 3 for instructions)

How would you score your skin problem from 0-10 today?

0 _____ 10

Completely Clear

Severely Affected Skin

Score Allocated:

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 7.4. TREATMENT EFFECT SCORES: 4 WEEKS

Investigator Global assessment of active disease post treatment

Score	Expected features			
	No improvement. Lesion remained active, having the same characteristics or becoming			
12	larger than prior to the start of treatment.			
9	Size of the lesion decreased 50% in comparison with the initial lesion, with fewer			
9	inflammatory signs and discrete re-epithelialization (Size: diameter, length & width)			
6	Size of the lesion decreased between 50–90% in comparison with the initial lesion, and left			
0	few inflammatory signs			
3	Size of the lesion decreased more than 90%, with re-epithelialization and very little			
3	inflammation.			
0	Complete re-epithelialization with a characteristic scar and no inflammation. Active disease			
0	settled			

*Inflammatory signs: erythema by clinical-eyeballing and having anticipated features expected with therapeutic

resolution of a lesion

7.5. SEQUELAE ASSESSMENTS: 4 WEEKS

Investigator Global Assessment of i & ii) Pigment change iii) Atrophic scars iv) Hypertrophic/ Keloid scars

Score (0-3)	Allocate Score		
Category	Score	Description	
	0	No hyperpigmentation	
	1	Mild hyperpigmentation	
	2	Moderate hyperpigmentation	
	3	Severe hyperpigmentation	
Score (0-3)	Pigment C	hange hypopigmentation	·
Category	Score	Description	
	0	No hypopigmentation	
	1	Mild hypopigmentation	
	2	Moderate hypopigmentation	
	3	Severe hypopigmentation	
Score (0-3)	Atrophic s	scars	
Category	Score	Description	
Clear	0	No scar visible or detectable on palpation	
Mild	1	Minimal atrophic scarring – little change on palpation	
Moderate	2	Atrophic scarring with textural changes of skin	
Severe	3	Deep atrophic / mutilating scar	
Score (0-3)	Hypertrop	phic / Keloid scars	
Category	Score	Description	
Clear	0	No scar visible or detectable on palpation	
Mild	1	Minimal hypertrophic scarring - some palpable change	
		Delegable second second states and shares a second states	
Moderate	2	Palpable scarring with textural changes of the skin	
Moderate Severe	2 3	Mutilating scar (with underlying structural involvement)	

7.6. HF	Coll: 4. WEEKS doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity.
1)	It is made available under a CC-BY 4.0 International license . How does your skin problem affect you?
2)	What are the 3 worst aspects of having your skin problem?


7.7. SUMMARY OF SCORES: 4 WEEKS

SCORE
(0-9)
(0-9)
(0-10)
(0-10)
SCORE
(0-12)
SCORE
(0-3)
(0-3)
(0-3)
(0-3)

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint 8. LOCALISED GLETANEOUS d. DISHUTANIASIS: the MONTLASE, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license .

8.1. 3 MONTH BIOPSY (IF TAKEN) AND INDEX LESION(S) FOR ASSESSMENT


- a) Please indicate on the figure below the site(s) of any biopsy(ies) taken and mark with a letter e.g. A
- b) Draw the lesion(s) biopsied in the box and indicate where the biopsy has been taken (M= medial L = lateral)
- c) Indicate features of the lesion(s) biopsied in the table below
- d) Distinguish any index lesion(s) for assessment throughout the study from the biopsy sites on the figures, and mark with a different letter.



Features of lesion(s) biopsied and under assessment. Please indicate	Lesion A	Lesion B	Lesion C	Lesion D
the clinical features of any lesion biopsied as well as any	Biopsy	Biopsy	Biopsy	Biopsy
other lesions undergoing assessment.	Y/N	Y/N	Y/N	Y/N
If possible please include the duration of the lesion (s).				
Macule (circumscribed change in the				
color of skin that is flat on palpation – (excludes scarring and post				
inflammatory pigmentary change)				
Papule (≤5mm diameter, palpable solid elevation)				
Nodule (>5 mm diameter, palpable elevation)				
Plaque (flat topped with diameter greater than its height)				
Ulcerative change				
Dry ulcer (destruction of epidermis of skin with central				
crusting/scaling)				
Wet ulcer (destruction of epidermis of skin with wet exudates)				
Nodular ulcerative (>5mm diameter, palpable elevation with central				
ulceration)				
Other features associated with the lesion(s)			•	
Satellite lesions				
Halo pigmentation				
Hyperpigmentation				
Hypopigmentation				
Atrophic Scarring				
Hypertrophic or Keloid scarring				
Duration of lesion if known				
Any other features – remarks				
Halo pigmentation Hyperpigmentation Hypopigmentation Atrophic Scarring Hypertrophic or Keloid scarring Duration of lesion if known				

8.2. OBJECTIVE ASSESSMENTS DB MONTHS 2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Area of Ulcer and Induration (See page 2 for instructions)



Please Indicate Site	Size of the ulcerated area if present 2 largest diameters		Total AreaArea of induratmm22 largest diamet			Total Area mm ²
	Diameter 1 (mm)	Diameter 2 (mm)	D1 x D2	Diameter 1 (mm)	Diameter 2 (mm)	D1 x D2

8.3. SUBJECTIVE ASSESSMENTS: 3 MONTHS

Assessment using a palpability score

For non-ulcerated areas measure by palpating the whole lesion and indicate a palpability score, as described. (See page 3 for instructions.)

Score Allocated:

For ulcerated lesions measure by palpating the EDGE of the lesion and allocate a score, as described. (See page 3 for instructions.)

Score Allocated:

Visual Analogue Score; Investigator's Score (See page 3 for instructions.)

How would you score this skin problem from 0-10 today?

0 — ____ 10

Completely Clear

Severely Affected Skin

Score Allocated:

Visual Analogue Score; Patient's Score (See page 3 for instructions.)

How would you score your skin problem from 0-10 today?

0 -- 10

Completely Clear

Severely Affected Skin

Score Allocated:

8.4. TREACTIVENTEEFFECT SCORES (MONTHS24.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Investigator Global assessment of active disease post treatment.

Score	Expected features	
12	No improvement. Lesion remained active, having the same characteristics or becoming	
12	larger than prior to the start of treatment.	
9	Size of the lesion decreased 50% in comparison with the initial lesion, with fewer	
5	inflammatory signs and discrete re-epithelialization (Size: diameter, length & width)	
6	Size of the lesion decreased between 50–90% in comparison with the initial lesion, and left	
0	few inflammatory signs	
3	Size of the lesion decreased more than 90%, with re-epithelialization and very little	
5	inflammation.	
0	Complete re-epithelialization with a characteristic scar and no inflammation. Active disease	
0	settled	

8.5. SEQUELAE ASSESSMENTS: 3 MONTHS

Investigator Global Assessment of i & ii) Pigment change iii) Atrophic scars iv) Hypertrophic/ Keloid scars

Score (0-3) I	Pigment Cl	hange hyperpigmentation	Allocate Score
Category	Score	Description	
	0	No hyperpigmentation	
	1	Mild hyperpigmentation	
	2	Moderate hyperpigmentation	
	3		
Score (0-3) I	Pigment Cl	hange hypopigmentation	
Category	Score	Description	
	0	No hypopigmentation	
	1	Mild hypopigmentation	
	2	Moderate hypopigmentation	
	3	Severe hypopigmentation	
Score (0-3)	Atrophic so	cars	
Category	Score	Description	
Clear	0	No scar visible or detectable on palpation	
Mild	1	Minimal atrophic scarring – little change on palpation	
Moderate	2	Atrophic scarring with textural changes of skin	
Severe	3	Deep atrophic / mutilating scar	
Score (0-3) I	Hypertrop	hic / Keloid scars	
Category	Score	Description	
Clear	0	No scar visible or detectable on palpation	
Mild	1ild 1 Minimal hypertrophic scarring - some palpable change		
Moderate	2	Palpable scarring with textural changes of the skin	
Severe	3	Mutilating scar (with underlying structural involvement)	
TOTAL SCOP	RE		

8.6.	ME	medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint ASURING: HRQOIX is MIDNEES eview) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
	1)	How does your skin problem affect you?
	2)	What are the 3 worst aspects of having your skin problem?

8.7. SUMMARY OF SCORES: 3 MONTHS

_	

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. 9. LOCALISED CUTANEOUS LEISHMANIA state was been a CC-BY 4.0 International license.

9.1 Baseline biopsy and index lesion(s) for assessment

- a) Please indicate on the figure below the site(s) of any biopsy(ies) taken and mark with a letter e.g. A
- b) Draw the lesion(s) biopsied in the box and indicate where the biopsy has been taken (M= medial L = lateral)
- c) Indicate features of the lesion(s) biopsied in the table below
- d) Distinguish any index lesion(s) for assessment throughout the study from the biopsy sites on the figures, and mark with a different letter.

by site at baseline (front) L		Biops	sy site at base	ine (back) L
Features of lesion(s) biopsied and under assessment. Please indicate	e Lesion A	Lesion B	Lesion C	Lesion
the clinical features of any lesion biopsied as well as any	Biopsy	Biopsy	Biopsy	Biopsy
other lesions undergoing assessment.	Y/N	Y/N	Y/N	Y/N
If possible please include the duration of the lesion (s).				
Macule (circumscribed change in the				
color of skin that is flat on palpation – (excludes scarring and post				
inflammatory pigmentary change)				
Papule (≤5mm diameter, palpable solid elevation)				
Nodule (>5 mm diameter, palpable elevation)				
Plaque (flat topped with diameter greater than its height)				
Ulcerative change				1
Dry ulcer (destruction of epidermis of skin with central				
crusting/scaling)				
Wet ulcer (destruction of epidermis of skin with wet exudates)				
Nodular ulcerative (>5mm diameter, palpable elevation with central				
ulceration)				
Other features associated with the lesion(s)				
Satellite lesions				
Halo pigmentation				
Hyperpigmentation	1			
		1		
		1	1	1
Hypopigmentation				
Hypopigmentation Atrophic Scarring				
Hypopigmentation				

9.2. OBJECTIVE ASSESSMENTS: D6:MONTHS:2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

Area of Ulcer and Induration; See page 2 for instructions



Please Indicate Site	Size of the ulc pres 2 largest c	sent	Total Area mm ²	Area of inc 2 largest di		Total Area mm ²
	Diameter 1 (mm)	Diameter 2 (mm)	D1 x D2	Diameter 1 (mm)	Diameter 2 (mm)	D1 x D2

9.3. SUBJECTIVE ASSESSMENTS: 6 MONTHS

Assessment using a palpability score

For non-ulcerated areas measure by palpating the whole lesion and indicate a palpability score, as described. See page 3 for instructions.

Score Allocated:

For ulcerated lesions measure by palpating the EDGE of the lesion and allocate a score, as described. See page 3 for instructions.

Score Allocated:

Visual Analogue Score; Investigator's Score (See page 3 for instructions)

How would you score this skin problem from 0-10 today?

0 — - 10

Completely Clear

Severely Affected Skin

Score Allocated:

Visual Analogue Score; Patient's Score (See page 3 for instructions)

How would you score your skin problem from 0-10 today?

0 — - 10

Completely Clear

Severely Affected Skin

9.4. TREATIMENT FFFECT SCORES of MONTHS4.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. Investigator Global assessment of active disease post treatment

Score	Expected features	Allocate Score
12	No improvement. Lesion remained active, having the same characteristics or becoming	
12	larger than prior to the start of treatment.	
9	Size of the lesion decreased 50% in comparison with the initial lesion, with fewer	
3	inflammatory signs and discrete re-epithelialization (Size: diameter, length & width)	
6	Size of the lesion decreased between 50–90% in comparison with the initial lesion, and	
0	left few inflammatory signs	
2	Size of the lesion decreased more than 90%, with re-epithelialization and very little	
5	inflammation.	
0	Complete re-epithelialization with a characteristic scar and no inflammation. Active	
0	disease settled	

9.5. SEQUELAE ASSESSMENTS: 6 MONTHS

Investigator Global Assessment of i & ii) Pigment change iii) Atrophic scars iv) Hypertrophic/ Keloid scars

Score (0-3)	Score (0-3) Pigment Change hyperpigmentation Allocate Score			
Category	Score	Description		
	0	No hyperpigmentation		
	1 Mild hyperpigmentation			
	2	Moderate hyperpigmentation		
	3	Severe hyperpigmentation		
Score (0-3)	Pigment C	hange hypopigmentation		
Category	Score	Description		
	0	No hypopigmentation		
	1	Mild hypopigmentation		
	2	Moderate hypopigmentation		
	3	Severe hypopigmentation		
Score (0-3)	Atrophic s	cars		
Category	Score	Description		
Clear	0	No scar visible or detectable on palpation		
Mild	1	Minimal atrophic scarring – little change on palpation		
Moderate	2	Atrophic scarring with textural changes of skin		
Severe	3	Deep atrophic / mutilating scar		
Score (0-3)	Hypertrop	hic / Keloid scars		
Category	Score	Description		
Clear	0	No scar visible or detectable on palpation		
Mild	1 Minimal hypertrophic scarring - some palpable change			
Moderate	2	Palpable scarring with textural changes of the skin		
Severe	3	Mutilating scar (with underlying structural involvement)		
TOTAL SCO	RE	•		

9.6.		edRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. QoL: 6 MONTHS It is made available under a CC-BY 4.0 International license.
:	1)	How does your skin problem affect you?
	2)	What are the 3 worst aspects of having your skin problem?

9.7. SUMMARY OF SCORES: 6 MONTHS

SUBJECTIVE	SCORE
Palpability; Non-ulcerated lesions	(0-9)
Palpability; Ulcerated lesions	(0-9)
Visual Analogue; Investigator	(0-10)
Visual Analogue; Patient	(0-10)
TOTAL	
TREATMENT EFFECT	SCORE
Investigator Assessment	(0-12)
TOTAL	
SEQUELAE ASSESSMENTS	SCORE
Pigment Change; Hyperpigmentation	(0-3)
Pigment Change; Hypopigmentation	(0-3)
Atrophic Scars	(0-3)
Hypertrophic/Keloid Scars	(0-3)
TOTAL	

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.

10. SUMMARY OF SCORES OVER TIME

SUBJECTIVE	BASELINE	4 WEEKS	3 MONTHS	6 MONTHS
Palpability; Non-ulcerated lesions				
Palpability; Ulcerated lesions				
Visual Analogue; Investigator				
Visual Analogue; Patient				
TREATMENT EFFECT				
Investigator Assessment	X			
SEQUELAE ASSESSMENTS				
Pigment Change; Hyperpigmentation				
Pigment Change; Hypopigmentation				
Atrophic Scars				
Hypertrophic/Keloid Scars				
HRQOL				

Release date: 19 June 2018

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. **11. Drug therapy related to Leishmahfasis:**

Dose (mg)/injection

	Route	Date* T1	Date T2	Date T3	Date T4	Date T5	Date T6	Date T7	Date T8	Date T9	Date T10	Duration of
		Date T11	Date T12	Date T13	Date T14	Date T15	Date T16	Date T17	Date T18	Date T19	Date T20	therapy
Amphotericin B												
Liposomal Amphotericin B												
Miltefosine												
Antimonials/ Sodium Stibogluconate												

*Date (DD/MM/YYYY)

12. Cytokine profiles in dermal Lesions:

Parameter	Baseline	At 4 weeks
Date		
IFN γ		
IL-2		
IL-10		
IL- 4		
TGF-β		
IL-13		
IL-12		
IL-17		

13. miRNA analysis of blood

Time point	Date	Availability Yes/No
Base line at "0" time point		
-		
At 4 weeks		

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. **14. Complete Blood Count, Blochemistra** de available in de listop B119, 982 matching de license to display the preprint in perpetuity.

Parameter	Baseline*	Post t/t 1	Post t/t 2	Post t/t 3	Post t/t 4	Post t/t 5	Post t/t 6	Post t/t 7	At complete healing*
Date									
Hb (g/dl)									
Haematocrit (PCV)(%)									
MCHC (g/dL)									
MCH (pg)									
MCV (fL)									
WBC Total (x10 ³ /mm ³)									
Neutrophils (%)									
Lymphocytes (%)									
Monocytes (%)									
Eosinophils (%)									
Basophils (%)									
RBC (x10 ⁶ /mm ³)									
Platelets (x10 ³ /mm ³)									
ESR (mm/hr)									
Bilirubin (mg/dl)									
ALT (IU/L)									
AST (IU/L)									
Albumin/Globulin									
Blood Urea (mg/dl)									
Serum Creatinine (mg/dl)									
Serum Electrolytes Na + (mmol /L)									
K+ (mmol /L) Serum Amylase (U/L)									
HbA1c (%)									
Skin Histopathology									

^{*} Blood parameters will be carried out in Sri Lankan patients only at "0" time point and at 4 weeks after initiating treatment. Page **26** of **27**

medRxiv preprint doi: https://doi.org/10.1101/2024.05.28.24307884; this version posted May 28, 2024. The copyright holder for this preprint **15. Final Impression (after completion or review)** is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. If is made available under a CC-BY 4.0 methational license.

16. Investigator's details: Name:

Signature:

Date:



GCRF Funded Project: MR/P024661/1 Towards a global research network for the molecular pathological stratification of leishmaniasis



viversity Vork









Page **27** of **27**